CAMP
CAMP4 Therapeutics CorporationNASDAQHealthcare$4.47+0.22%ClosedMarket Cap: $94.9M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.86
P/S
27.14
EV/EBITDA
0.24
DCF Value
$3.00
FCF Yield
-31.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.5%
Operating Margin
-1488.3%
Net Margin
-2298.5%
ROE
-162.5%
ROA
-68.2%
ROIC
-50.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $348.0K | $-40.3M | $-0.78 |
| FY 2025 | $3.5M | $-80.4M | $-2.65 |
| Q3 2025 | $795.0K | $-15.1M | $-0.55 |
| Q2 2025 | $1.5M | $-12.6M | $-0.62 |
Analyst Ratings
View AllLeerink PartnersOutperform
2026-04-02JP MorganNeutral
2025-09-16Piper SandlerOverweight
2025-09-15Trading Activity
Insider Trades
View AllMandel-Brehm Joshdirector, officer: Chief Executive Officer
SellFri Apr 03
Gold Kellyofficer: Chief Financial Officer
SellFri Apr 03
Maricich Yuriofficer: Chief Medical Officer
SellFri Apr 03
Tardiff Danielofficer: Chief Scientific Officer
SellFri Apr 03
MacLean Michael Fdirector:
SellFri Apr 03
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.36
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.